<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.1 20050630//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Crit Care</journal-id><journal-title>Critical Care</journal-title><issn pub-type="ppub">1364-8535</issn><issn pub-type="epub">1466-609X</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">cc2337</article-id><article-id pub-id-type="pmid">14624682</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Science Review: Vasopressin and the cardiovascular system part 1 &#x02013; receptor physiology</article-title></title-group><contrib-group><contrib id="A1" contrib-type="author"><name><surname>Holmes</surname><given-names>Cheryl L</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib id="A2" contrib-type="author"><name><surname>Landry</surname><given-names>Donald W</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib id="A3" corresp="yes" contrib-type="author"><name><surname>Granton</surname><given-names>John T</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>John.Granton@uhn.on.ca</email></contrib></contrib-group><aff id="I1"><label>1</label>Staff intensivist, Department of Medicine, Division of Critical Care, Kelowna General Hospital, Kelowna BC, Canada</aff><aff id="I2"><label>2</label>Associate Professor, Department of Medicine, Columbia University, New York, New York, USA</aff><aff id="I3"><label>3</label>Assistant Professor of Medicine, Faculty of Medicine, and Program Director, Critical Care Medicine, University of Toronto, and Consultant in Pulmonary and Critical Care Medicine, Director Pulmonary Hypertension Program, University Health Network, Toronto, Ontario, Canada</aff><pub-date pub-type="ppub"><year>2003</year></pub-date><pub-date pub-type="epub"><day>26</day><month>6</month><year>2003</year></pub-date><volume>7</volume><issue>6</issue><fpage>427</fpage><lpage>434</lpage><copyright-statement>Copyright &#x000a9; 2003 BioMed Central Ltd</copyright-statement><abstract><p>Vasopressin is emerging as a rational therapy for vasodilatory shock states. Unlike other vasoconstrictor agents, vasopressin also has vasodilatory properties. The goal of the present review is to explore the vascular actions of vasopressin. In part 1 of the review we discuss structure, signaling pathways, and tissue distributions of the classic vasopressin receptors, namely V<sub>1 </sub>vascular, V<sub>2 </sub>renal, V<sub>3 </sub>pituitary and oxytocin receptors, and the P<sub>2 </sub>class of purinoreceptors. Knowledge of the function and distribution of vasopressin receptors is key to understanding the seemingly contradictory actions of vasopressin on the vascular system. In part 2 of the review we discuss the effects of vasopressin on vascular smooth muscle and the heart, and we summarize clinical studies of vasopressin in shock states.</p></abstract><kwd-group><kwd>adrenergic agents</kwd><kwd>antidiurectic hormone</kwd><kwd>cardiac inotropy</kwd><kwd>hypotension</kwd><kwd>nitric oxide</kwd><kwd>oxytocin</kwd><kwd>physiology</kwd><kwd>potassium channels</kwd><kwd>receptors</kwd><kwd>septic shock</kwd><kwd>smooth muscle</kwd><kwd>vasoconstriction</kwd><kwd>vascular</kwd><kwd>vasodilation</kwd><kwd>vasopressin</kwd></kwd-group></article-meta></front><body><sec><title>Introduction</title><p>Arginine vasopressin (hereafter referred to as vasopressin), also known as antidiuretic hormone, is essential for survival, as attested by its teleologic persistence. Oxytocin- and vasopressin-like peptides have been isolated from four invertebrate phyla and the seven major vertebrate families, representing more than 120 species [<xref ref-type="bibr" rid="B1">1</xref>]. Therefore, the ancestral gene encoding the precursor protein appears to antedate the divergence of the vertebrate and invertebrate families, about 700 million years ago [<xref ref-type="bibr" rid="B2">2</xref>]. Virtually all vertebrate species possess an oxytocin-like and a vasopressin-like peptide, and so two evolutionary lineages can be traced. The presence of a single peptide, vasotocin ([Ile3]-vasopressin or [Arg8]-oxytocin), in the most primitive cyclostomata supports the notion that primordial gene duplication with subsequent mutations gave rise to the two lineages [<xref ref-type="bibr" rid="B2">2</xref>].</p><p>Vasopressin is essential for cardiovascular homeostasis. The vasopressor effect of pituitary extract, first observed in 1895, was attributed to the posterior lobe of this gland [<xref ref-type="bibr" rid="B3">3</xref>]. It was not until 18 years later that the antidiuretic effect of neurohypophyseal extract was demonstrated [<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B5">5</xref>]. After isolation and synthesis of vasopressin in the 1950s, it was proven that the same hormone in the posterior pituitary possessed both antidiuretic and vasopressor effects [<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B7">7</xref>]. The importance of vasopressin in osmotic defense is fundamental. Indeed, the antidiuretic effect of vasopressin has been exploited clinically for over half a century to treat diabetes insipidus. Only recently has vasopressin emerged as a therapy for shock states, renewing interest in the cardiovascular effects of vasopressin.</p><p>Shock states induce an increase in vasopressin levels from 20- to 200-fold [<xref ref-type="bibr" rid="B8">8</xref>-<xref ref-type="bibr" rid="B12">12</xref>]. These supraphysiologic levels cause profound vasoconstriction and help to maintain end-organ perfusion [<xref ref-type="bibr" rid="B13">13</xref>,<xref ref-type="bibr" rid="B14">14</xref>]. Prolonged shock is associated with a fall in vasopressin levels [<xref ref-type="bibr" rid="B15">15</xref>-<xref ref-type="bibr" rid="B18">18</xref>], probably due to depletion of vasopressin stores [<xref ref-type="bibr" rid="B19">19</xref>,<xref ref-type="bibr" rid="B20">20</xref>], and may contribute to the refractory hypotension that is seen in advanced shock states. Paradoxically, vasopressin has also been demonstrated to cause vasodilation in some vascular beds [<xref ref-type="bibr" rid="B21">21</xref>-<xref ref-type="bibr" rid="B28">28</xref>], distinguishing this hormone from other vasoconstrictor agents.</p><p>The present review explores the vascular actions of vasopressin. First, a discussion of the signaling pathways and distribution of vasopressin receptors is necessary to gain an understanding of the seemingly paradoxic vasodilatory and vasoconstrictor actions of vasopressin. We discuss the structural elements responsible for the functional diversity found within the vasopressin receptor family. In part 2 of our review, we explore the mechanisms of vasoconstriction and vasodilation of the vascular smooth muscle, with an emphasis on vasopressin interaction in these pathways. We review the seemingly contradictory studies and some new information regarding the actions of vasopressin on the heart. Finally, we summarize the clinical trials of vasopressin in vasodilatory shock states and comment on areas for future research.</p></sec><sec><title>Overview of vasopressin</title><sec><title>Structure of the hormone and the genes</title><p>Vasopressin is a nonapeptide with a disulfide bridge between two cysteine amino acids [<xref ref-type="bibr" rid="B29">29</xref>] and is synthesized by the magnocellular neurons of the hypothalamus [<xref ref-type="bibr" rid="B30">30</xref>] (Fig. <xref ref-type="fig" rid="F1">1</xref>). Although oxytocin differs from vasopressin by only one amino acid (80% homology), they have clearly divergent physiologic activity. Vasopressin is involved in osmotic and cardiovascular homeostasis, whereas oxytocin is important in parturition, lactation, and sexual behavior.</p><p>Oxytocin and vasopressin are encoded by separate genes but they lie on the same chromosome, at 20p [<xref ref-type="bibr" rid="B31">31</xref>], separated by a segment of DNA only 12 kilobases long [<xref ref-type="bibr" rid="B32">32</xref>]. The similarities in structure as well as the close apposition are suggestive of recent gene duplication [<xref ref-type="bibr" rid="B33">33</xref>]. Despite ample documentation of cell-specific expression and physiologic regulation of the vasopressin gene, there is striking lack of progress in identifying transcription factors that act on the vasopressin promoter [<xref ref-type="bibr" rid="B34">34</xref>].</p></sec><sec><title>Structure of the receptor</title><p>The actions of vasopressin are mediated by stimulation of tissue-specific G-protein-coupled receptors (GPCRs), which are currently classified into V<sub>1 </sub>vascular (V<sub>1</sub>R), V<sub>2 </sub>renal (V<sub>2</sub>R), V<sub>3 </sub>pituitary (V<sub>3</sub>R) and oxytocin (OTR) subtypes [<xref ref-type="bibr" rid="B35">35</xref>] and P<sub>2 </sub>purinergic receptors (P<sub>2</sub>R) [<xref ref-type="bibr" rid="B36">36</xref>]. The GPCRs are comprised of seven hydrophobic transmembrane &#x003b1;-helices joined by alternating intracellular and extracellular loops, an extracellular amino-terminal domain, and a cytoplasmic carboxyl-terminal domain (Fig. <xref ref-type="fig" rid="F2">2</xref>) [<xref ref-type="bibr" rid="B29">29</xref>]. The actions of vasopressin are signaled through pathways that are similar to extracellular agents such as hormones (glucagon, luteinizing hormone, and epinephrine [adrenaline]), neurotransmitters (acetylcholine, dopamine, and serotonin) and chemokines (interleukin-8). Local mediators signal to the four main G protein families to regulate cellular machinery such as metabolic enzymes, ion channels, and transcriptional regulators [<xref ref-type="bibr" rid="B37">37</xref>]. The extracellular signals are routed to specific G proteins through distinct types of receptors. For example, epinephrine's signal is transmitted through the &#x003b2;-adrenergic receptor coupled to G<sub>i</sub>, and the &#x003b1;<sub>1</sub>-adrenergic receptor coupled to G<sub>q </sub>and G<sub>11</sub>. Many important hormones, including epinephrine, acetylcholine, dopamine, and serotonin, interact with the G<sub>i </sub>pathway, which is characterized by inhibition of adenylyl cyclase [<xref ref-type="bibr" rid="B37">37</xref>].</p><p>Agonist stimulation of vasopressin receptors leads to receptor subtype-specific interactions with G-protein-coupled receptor kinases (GRKs) and protein kinase C (PKC) through specific motifs that are present in the carboxyl termini of the receptors [<xref ref-type="bibr" rid="B38">38</xref>]. Guanine nucleotide-binding proteins (G-proteins) are signal transducers, attached to the cell surface membrane, that connect receptors to effectors and thus to intracellular signaling pathways [<xref ref-type="bibr" rid="B39">39</xref>]. Functional characterization of the G-proteins, including G<sub>s</sub>, G<sub>i/o</sub>, G<sub>q/11</sub>, and G<sub>12/13 </sub>[<xref ref-type="bibr" rid="B37">37</xref>], indicates that a single receptor can activate multiple second messenger pathways through interaction with one or more G-proteins [<xref ref-type="bibr" rid="B40">40</xref>-<xref ref-type="bibr" rid="B42">42</xref>].</p><p>Vasopressin's signal is transmitted through both G<sub>s </sub>and G<sub>q/11 </sub>subtypes [<xref ref-type="bibr" rid="B37">37</xref>]. The G<sub>s </sub>pathway is characterized by inhibition of adenylyl cyclase, leading to increased levels of cAMP that in turn connects to multiple cellular machines, including ion channels, transcription factors, and metabolic enzymes. Both &#x003b2;-adrenergic receptors and vasopressin receptors regulate G<sub>s </sub>protein signaling. The G<sub>q/11 </sub>pathway is the classical pathway that is activated by calcium-mobilizing hormones and stimulates phospholipase-&#x003b2; to produce the intracellular messengers inositol trisphosphate and diacylglycerol (DAG) [<xref ref-type="bibr" rid="B37">37</xref>]. Inositol trisphosphate triggers the release of calcium from intracellular stores and DAG recruits PKC to the membrane and activates it. The &#x003b1;-subunit of G<sub>q </sub>also activates the transcription factor nuclear factor-&#x003ba;B [<xref ref-type="bibr" rid="B43">43</xref>].</p></sec></sec><sec><title>The V<sub>1 </sub>receptor</title><p>The V<sub>1</sub>R gene is located on chromosome 12 and maps to region 12q14-15 [<xref ref-type="bibr" rid="B44">44</xref>]. Functionally, the V<sub>1</sub>R activates G-proteins of the G<sub>q/11 </sub>family. The &#x003b1;-subunits regulate the activity of the &#x003b2;-isoforms of phospholipase C [<xref ref-type="bibr" rid="B29">29</xref>]. A variety of signaling pathways is associated with the V<sub>1</sub>R, and these pathways include activation of calcium influx, phospholipase A<sub>2</sub>, phospholipase C, and phospholipase D [<xref ref-type="bibr" rid="B45">45</xref>].</p><p>V<sub>1</sub>Rs are found in high density on vascular smooth muscle and cause vasoconstriction by an increase in intracellular calcium via the phosphatidyl&#x02013;inositol-bisphosphonate cascade. Cardiac myocytes also possess the V<sub>1</sub>R and are discussed in part 2 of the review. Additionally, V<sub>1</sub>Rs are located in brain, testis, superior cervical ganglion, liver, blood vessels, and renal medulla [<xref ref-type="bibr" rid="B46">46</xref>]. The exact physiologic role of vasopressin in many of these diverse tissues remains unknown.</p><p>Platelets express the V<sub>1</sub>R, which upon stimulation induces an increase in intracellular calcium, facilitating thrombosis [<xref ref-type="bibr" rid="B47">47</xref>]. However, there appears to be tremendous variability in the aggregation response of normal human platelets to vasopressin [<xref ref-type="bibr" rid="B48">48</xref>]. Based on kinetic studies and the effects of PKC inhibition on the aggregation response to vasopressin, significant heterogeneity in the aggregation response of normal human platelets to vasopressin has been demonstrated, which is probably related to a polymorphism of the platelet V<sub>1</sub>R [<xref ref-type="bibr" rid="B49">49</xref>].</p><p>V<sub>1</sub>Rs are found in the kidney, where they occur in high density on medullary interstitial cells, vasa recta, and epi thelial cells of the collecting duct. Vasopressin acts on medullary vasculature through the V<sub>1</sub>R to reduce blood flow to inner medulla without affecting blood flow to outer medulla [<xref ref-type="bibr" rid="B50">50</xref>]. V<sub>1</sub>Rs on the luminal membrane of the collecting duct probably exerted through V<sub>1a </sub>receptors located on luminal membrane limit the antidiuretic effects of vasopressin [<xref ref-type="bibr" rid="B50">50</xref>]. Interestingly, cyclosporine A induces upregulation of V<sub>1</sub>R mRNA in vascular smooth muscle [<xref ref-type="bibr" rid="B51">51</xref>], increasing the number of V<sub>1</sub>Rs by twofold [<xref ref-type="bibr" rid="B52">52</xref>], which could be a key mechanism by which cyclosporine A causes both hypertension and reduced glomerular filtration. Additionally, vasopressin selectively contracts efferent arterioles [<xref ref-type="bibr" rid="B53">53</xref>], probably through the V<sub>1</sub>R, but not the afferent arteriole. This selectivity, which is not shared by catecholamine vasopressors, would tend to increase glomerular filtration, probably accounting for the paradoxic increase in urine output observed when this antidiuretic hormone is administered to patients in vasodilatory shock [<xref ref-type="bibr" rid="B54">54</xref>,<xref ref-type="bibr" rid="B55">55</xref>].</p><p>There is considerable interspecies variation in the V<sub>1</sub>R. For instance, although rat and human vasopressin are identical, the human V<sub>1</sub>R is only 80% homologous with the rat V<sub>1</sub>R [<xref ref-type="bibr" rid="B1">1</xref>]. This must be kept in mind when interpreting animal studies aimed at interpreting receptor subtypes based on the use of specific receptor inhibitors.</p></sec><sec><title>The V<sub>2 </sub>receptor</title><p>The V<sub>2 </sub>R differs from the V<sub>1</sub>R primarily in the number of sites susceptible to N-linked glycosylation; the V<sub>1</sub>R has sites at both the amino-terminus and at the extracellular loop, whereas the V<sub>2</sub>R has a single site at the extracellular amino-terminus [<xref ref-type="bibr" rid="B56">56</xref>]. Despite structural similarities, the V<sub>2</sub>R differs functionally from the V<sub>1</sub>R. Mutagenesis experiments involving the V<sub>1</sub>R and V<sub>2</sub>R have confirmed that the short sequence at the amino-terminus of the cytoplasmic tail confers V<sub>2 </sub>receptor&#x02013;G<sub>s </sub>coupling selectivity. The efficiency of V<sub>2</sub>R&#x02013;G<sub>s </sub>coupling can be modulated by the length of the central portion of the third intracellular loop [<xref ref-type="bibr" rid="B57">57</xref>], whereas the second intracellular loop of the V<sub>1</sub>R is critically involved in selective activation of G<sub>q/11 </sub>[<xref ref-type="bibr" rid="B58">58</xref>].</p><p>The well known antidiuretic effect of vasopressin occurs via activation of the V<sub>2</sub>R. Vasopressin regulates water excretion from the kidney by increasing the osmotic water permeability of the renal collecting duct &#x02013; an effect that is explained by coupling of the V<sub>2</sub>R with the G<sub>s </sub>signaling pathway, which activates cAMP [<xref ref-type="bibr" rid="B59">59</xref>]. The increased intracellular cAMP in the kidney [<xref ref-type="bibr" rid="B60">60</xref>,<xref ref-type="bibr" rid="B61">61</xref>] in turn triggers fusion of aquaporin-2-bearing vesicles with the apical plasma membrane of the collecting duct principal cells, increasing water reabsorption [<xref ref-type="bibr" rid="B62">62</xref>]. Vasopressin regulates water homeostasis in two ways: regulation of the fast shuttling of aquaporin 2 to the cell surface and stimulation of the synthesis of mRNA encoding aquaporin 2 [<xref ref-type="bibr" rid="B63">63</xref>]. Most cases of diabetes insipidus can be explained by mutations in the V<sub>2</sub>R gene, which is located on chromosome region 10q28 [<xref ref-type="bibr" rid="B64">64</xref>]. For example, an Arg137&#x02192;His mutation in the V<sub>2</sub>R abolishes coupling to the G<sub>s </sub>protein, causing a complete phenotype of nephrogenic diabetes insipidus [<xref ref-type="bibr" rid="B65">65</xref>].</p><p>It has been postulated that the V<sub>2</sub>R is also expressed in endothelium because the potent V<sub>2</sub>R agonist 1-deamino-8-D-arginine vasopressin (DDAVP) causes both release of von Willebrand factor and vasodilation [<xref ref-type="bibr" rid="B21">21</xref>]. Previous studies of the localization and distribution of different vasopressin receptors have been hampered by the use of nonselective radioligands such as [<sup>3</sup>H]arginine vasopressin, which binds to all types of V<sub>1</sub>R and V<sub>2</sub>R, certain OTRs, and neurophysins. When selective V<sub>1</sub>R and V<sub>2</sub>R radioligands with <italic>in vitro </italic>auto-radiography were used to study V<sub>1</sub>R and V<sub>2</sub>R binding sites, no binding was demonstrated on endothelium or liver, where DDAVP might influence clotting factor release, or in the brain, spinal cord, sympathetic ganglia, heart or vascular smooth muscle &#x02013; regions where DDAVP might cause vasodilation [<xref ref-type="bibr" rid="B46">46</xref>]. Specific binding was only identified in the kidney, which is consistent with the known distribution of antidiuretic V<sub>2</sub>Rs on renal collecting tubules.</p></sec><sec><title>The V<sub>3 </sub>receptor</title><p>The human V<sub>3</sub>R (previously known as V<sub>1b</sub>R) is a G-protein-coupled pituitary receptor that, because of its scarcity, was only recently characterized. The V<sub>3</sub>R gene maps to chromosome region 1q32 [<xref ref-type="bibr" rid="B66">66</xref>]. The 424-amino-acid sequence of the V<sub>3</sub>R has homologies of 45%, 39%, and 45% with the V<sub>1</sub>R, V<sub>2</sub>R, and OTR, respectively [<xref ref-type="bibr" rid="B67">67</xref>]. However, the V<sub>3</sub>R has a pharmacologic profile that distinguishes it from the human V<sub>1</sub>R and activates several signaling pathways via different G-proteins, depending on the level of receptor expression [<xref ref-type="bibr" rid="B68">68</xref>]. Interestingly the V<sub>3</sub>R is also is over-expressed in adrenocorticotropic hormone (ACTH)-hypersecreting tumors.</p><p>More than one G-protein appears to participate in signal transduction pathways linked to V<sub>3</sub>Rs, depending on the level of receptor expression and the concentration of vasopressin [<xref ref-type="bibr" rid="B69">69</xref>]. For instance, vasopressin causes secretion of ACTH from the anterior pituitary cells in a dose-dependent manner through activation of PKC [<xref ref-type="bibr" rid="B70">70</xref>] via the G<sub>q/11 </sub>class [<xref ref-type="bibr" rid="B68">68</xref>]. Other cellular responses, including increased synthesis of DNA and cAMP, which are important in the induction and phenotype maintenance of ACTH-secreting tumors, are mediated through recruitment of several pathways, including G<sub>s</sub>, G<sub>i</sub>, and G<sub>q/11 </sub>[<xref ref-type="bibr" rid="B68">68</xref>]. The V<sub>3</sub>R has been inferred to exist in the pancreas [<xref ref-type="bibr" rid="B71">71</xref>] on the basis of antagonist studies; however, this conclusion may be suspect because significant homology exists between the V<sub>3</sub>R and the V<sub>1</sub>R [<xref ref-type="bibr" rid="B59">59</xref>].</p></sec><sec><title>The oxytocin receptor</title><p>The OTR can be considered a 'nonselective' vasopressin receptor. The OTR has equal affinity for vasopressin and oxytocin, whereas the V<sub>1</sub>R has a 30-fold higher affinity for vasopressin than for oxytocin [<xref ref-type="bibr" rid="B72">72</xref>]. OTRs are functionally coupled to G<sub>q/11 </sub>class binding proteins, which stimulate the activity of phospholipase C [<xref ref-type="bibr" rid="B73">73</xref>]. This leads to the generation of inositol trisphosphate and 1,2-DAG. Inositol trisphosphate triggers calcium release from intracellular stores, whereas DAG stimulates PKC, which phosphorylates unidentified target proteins [<xref ref-type="bibr" rid="B73">73</xref>]. A variety of cellular events are initiated in response to an increase in intracellular calcium. For example, the forming calcium&#x02013;calmodulin complexes trigger activation of neuronal and endothelial isoforms of nitric oxide synthase. Nitric oxide in turn stimulates the soluble guanylate cyclase to produce cGMP, leading to vasodilation. In smooth muscle cells, the calcium&#x02013;calmodulin system triggers the activation of myosin light chain kinase activity, which initiates smooth muscle contraction (e.g. in myometrial or mammary myoepithelial cells) [<xref ref-type="bibr" rid="B74">74</xref>]. In neurosecretory cells, rising calcium levels control cellular excitability, modulate their firing patterns, and lead to transmitter release. Further calcium-promoted processes include gene transcription and protein synthesis.</p><p>OTRs have been localized to a variety of reproductive and nonreproductive tissues [<xref ref-type="bibr" rid="B73">73</xref>]. Importantly, OTRs exist in high density on vascular endothelium, mediating nitric oxide dependent vasodilation [<xref ref-type="bibr" rid="B75">75</xref>]. Recently, the oxytocin/OTR system has been discovered in the heart. Activation of cardiac OTR stimulates the release of atrial natriuretic peptide, which is involved in natriuresis, regulation of blood pressure, and cell growth [<xref ref-type="bibr" rid="B76">76</xref>]. Embryonic stem cells exposed to oxytocin exhibit increased atrial natriuretic peptide mRNA and abundant mitochondria, and express sarcomeric myosin heavy chain, which is consistent with promotion of cardiomyocyte differentiation [<xref ref-type="bibr" rid="B77">77</xref>].</p></sec><sec><title>Purinergic receptors</title><p>Recently, vasopressin was demonstrated to act on the P<sub>2 </sub>class of purinoreceptors (P<sub>2</sub>Rs) [<xref ref-type="bibr" rid="B36">36</xref>]. P<sub>2</sub>Rs also belong to the seven-transmembrane-domain GPCR superfamily. ATP released from platelets and damaged cells bind endothelial P<sub>2</sub>Rs [<xref ref-type="bibr" rid="B78">78</xref>]. ATP can act on either of the two subclasses of purinoceptors, namely P<sub>2&#x003b3; </sub>and P<sub>2&#x003bd;</sub>. In both cases, activation of phospholipase C leads to mobilization of intracellular calcium stores. This binding stimulates phospholipase A<sub>2 </sub>and nitric oxide synthase, resulting in increased synthesis and release of prostacyclin and nitric oxide, respectively, and causing vascular smooth muscle vasodilation [<xref ref-type="bibr" rid="B78">78</xref>].</p><p>Purinoreceptors may also have an important role in cardiac contractility. ATP released by platelets, endothelial cells, and damaged myocardium activates the P<sub>2</sub>R, causing a large increase in cytosolic calcium and myocyte contractile amplitude [<xref ref-type="bibr" rid="B79">79</xref>]. ATP is also released as a cotransmitter with norepinephrine from sympathetic nerve endings and acts in a synergistic manner with &#x003b2;-adrenergic agents, increasing myocardial contractility [<xref ref-type="bibr" rid="B80">80</xref>]. In contrast to &#x003b2;-adrenergic agents, inotropy is not accompanied by a positive chronotropic effect. It is speculated that P<sub>2</sub>R agonist-stimulated increase in contractility could occur without the expense of a rate-related increase in myocardial oxygen demand [<xref ref-type="bibr" rid="B79">79</xref>].</p><p>Recently, vasopressin was shown to exert cardiac effects through activation of P<sub>2</sub>Rs expressed on cardiac endothelium. Intracoronary infusion of vasopressin-dextran (confines vasopressin to the intravascular space) and vasopressin at maximal concentration in isolated perfused guinea pig hearts caused coronary vasoconstriction and negative inotropy-effects that were blocked with vasopressin antagonists and P<sub>2</sub>R antagonist [<xref ref-type="bibr" rid="B36">36</xref>]. Caution must be exercised in interpreting this study because activation of P<sub>2</sub>Rs and increased levels of ATP normally increase inotropy. Furthermore, the same experiments performed in isolated perfused rat hearts demonstrated positive inotropy &#x02013; an effect that was blocked by P<sub>2</sub>R antagonists [<xref ref-type="bibr" rid="B36">36</xref>]. Further study is necessary to ascertain the significance of vasopressin P<sub>2</sub>R activation in the human heart, but the discovery that vasopressin acts on P<sub>2</sub>Rs is intriguing.</p><p>A number of pharmacologic observations have suggested the existence of vasopressin receptor/OTR subtypes beyond the five described above [<xref ref-type="bibr" rid="B72">72</xref>]. These include receptors for the metabolites of vasopressin and oxytocin (VP4-9 R and OT4-9 R) [<xref ref-type="bibr" rid="B72">72</xref>], and a cAMP-coupled vasopressin receptor with a V<sub>1</sub>-like pharmacologic profile termed V<sub>2b </sub>[<xref ref-type="bibr" rid="B81">81</xref>]. A novel 'vasotocin-like' receptor subtype has also been proposed [<xref ref-type="bibr" rid="B82">82</xref>].</p></sec><sec><title>Vasopressin/oxytocin receptor downregulation</title><p>Upon ligand binding, GPCRs undergo activation followed by a decrease in receptor responsiveness (desensitization). Agonist-dependent desensitization of these receptors can reduce their signaling responsiveness to maximum stimulation by up to 70&#x02013;80% [<xref ref-type="bibr" rid="B83">83</xref>]. Receptor desensitization occurs when activated receptors become phosphorylated and bind to &#x003b2;-arrestin proteins, inhibiting further interaction with G-proteins [<xref ref-type="bibr" rid="B84">84</xref>,<xref ref-type="bibr" rid="B85">85</xref>]. Receptor responsiveness is also limited by the degradation of cAMP by phosphodiesterases. &#x003b2;-Arrestins coordinate both phosphorylation of receptors and the rate of cAMP degradation by phosphodiesterases [<xref ref-type="bibr" rid="B85">85</xref>].</p><p>Exposure to vasopressin leads to desensitization of the V<sub>1</sub>R, which occurs quickly and is accompanied by sequestration of receptors inside the cell [<xref ref-type="bibr" rid="B59">59</xref>]. The V<sub>1</sub>R can also be desensitized by angiotensin II [<xref ref-type="bibr" rid="B86">86</xref>]. Compared with V<sub>1</sub>Rs and &#x003b2;<sub>2</sub>-adrenergic receptors, which are known to recycle and resensitize rapidly, the V<sub>2</sub>R recycles and resensitizes slowly [<xref ref-type="bibr" rid="B87">87</xref>]. Mutagenesis experiments demonstrate that the interaction of &#x003b2;-arrestin with a specific motif in the GPCR carboxyl-terminal tail dictates the rate of receptor dephosphorylation, recycling, and resensitization [<xref ref-type="bibr" rid="B87">87</xref>,<xref ref-type="bibr" rid="B88">88</xref>]. The clinical importance of vasopressin desensitization of the vasopressin receptor/ OTR family in human disease states is currently unknown.</p><p>Despite the clinical importance of the vasopressin receptors and OTRs, little is known about the mechanisms by which they undergo internalization and desensitization. Agonist activation of all vasopressin receptor/OTR subtypes leads to a specific physical association of the receptors with GRKs and/or PKC, following different time courses that are specific to the receptor subtype [<xref ref-type="bibr" rid="B38">38</xref>]. The pattern of interaction with GRKs and PKC is also unique to each vasopressin receptor subtype and occurs at the level of their carboxyl-termini [<xref ref-type="bibr" rid="B38">38</xref>].</p><p>Vasopressin is known to modulate the effect of other vasoactive agents [<xref ref-type="bibr" rid="B89">89</xref>,<xref ref-type="bibr" rid="B90">90</xref>] &#x02013; an interaction that may be explained by arrestin trafficking. Isoproterenol-dependent internalization of &#x003b2;<sub>2</sub>-adrenergic receptors is specifically blocked (&#x0003e;65% inhibition) by vasopressin-induced activation of V<sub>2</sub>Rs coexpressed at similar levels [<xref ref-type="bibr" rid="B42">42</xref>]. &#x003b2;<sub>2</sub>-Adrenergic receptors caused no detectable effect on V<sub>2</sub>R internalization in the same cells. There is evidence to suggest that this nonreciprocal inhibition of endocytosis is mediated by receptor-specific intracellular trafficking of &#x003b2;-arrestins [<xref ref-type="bibr" rid="B42">42</xref>]. Interestingly, interaction of vasopressin with arrestins and resistance of vasopressin receptors to downregulation may explain the reported ability of vasopressin to bypass desensitized myocardial adrenergic receptors in an experimental model of congestive heart failure [<xref ref-type="bibr" rid="B91">91</xref>]. The clinical importance of vasopressin upregulation of adrenergic receptors in critically ill humans is an important area for further study.</p></sec><sec><title>Conclusion</title><p>During the past 10 years, considerable progress has been made in our understanding of vasopressin receptor structure and function. The physiologic significance of the various receptors has been elucidated by the development of specific agonists and antagonists, particularly by Dr Maurice Manning's group [<xref ref-type="bibr" rid="B92">92</xref>-<xref ref-type="bibr" rid="B94">94</xref>]. An understanding of the molecular basis of receptor function will greatly aid in the development of new molecules with high selectivity for the different subtypes of receptors, and will have potential therapeutic significance, not only for conditions as diverse as hypertension, diabetes insipidus and premature labor, but also in vasodilatory shock with organ dysfunction. In part 2 of the review, we discuss the interaction of vasopressin with its various receptors in vascular smooth muscle and the heart, and its potential utility in vasodilatory shock states.</p></sec><sec><title>Competing interests</title><p>None declared.</p></sec><sec><title>Abbreviations</title><p>ACTH = adrenocorticotropic hormone; DAG = diacylglycerol; DDAVP = 1-deamino-8-D-arginine vasopressin; GPCR = G-protein-coupled receptor; GRK = G protein-coupled receptor kinase; OTR = oxytocin receptor; PKC = protein kinase C; P<sub>2</sub>R = P<sub>2 </sub>purinergic receptors; V<sub>1</sub>R = V<sub>1 </sub>vascular receptor; V<sub>2</sub>R = V<sub>2 </sub>renal receptor; V<sub>3</sub>R = V<sub>3 </sub>pituitary receptor.</p></sec></body><back><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hoyle</surname><given-names>CH</given-names></name></person-group><article-title>Neuropeptide families and their receptors: evolutionary perspectives</article-title><source>Brain Res</source><year>1999</year><volume>848</volume><fpage>1</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">10612694</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Acher</surname><given-names>R</given-names></name><name><surname>Chauvet</surname><given-names>J</given-names></name><name><surname>Chauvet</surname><given-names>MT</given-names></name></person-group><article-title>Man and the chimaera. Selective versus neutral oxytocin evolution</article-title><source>Adv Exp Med Biol</source><year>1995</year><volume>395</volume><fpage>615</fpage><lpage>627</lpage><pub-id pub-id-type="pmid">8714026</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oliver</surname><given-names>H</given-names></name><name><surname>Schaefer</surname><given-names>EA</given-names></name></person-group><article-title>On the physiological action of extracts of the pituitary body and certain other glandular organs</article-title><source>J Physiol (Lond)</source><year>1895</year><volume>18</volume><fpage>277</fpage><lpage>279</lpage></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>von den Velden</surname><given-names>R</given-names></name></person-group><article-title>The renal effects of hypophyseal extract in humans [in German]</article-title><source>Berl Klin Wochenscgr</source><year>1913</year><volume>50</volume><fpage>2083</fpage><lpage>2086</lpage></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Verney</surname><given-names>EB</given-names></name></person-group><article-title>The antidiuretic hormone and the factor which determines its release</article-title><source>Proc R Soc Lond (Biol)</source><year>1947</year><volume>135</volume><fpage>25</fpage><lpage>106</lpage></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Turner</surname><given-names>RA</given-names></name><name><surname>Pierce</surname><given-names>JG</given-names></name><name><surname>Du Vigneaud</surname><given-names>V</given-names></name></person-group><article-title>The purification and the amino acid content of vasopressin preparation</article-title><source>J Biol Chem</source><year>1951</year><volume>191</volume><fpage>21</fpage><pub-id pub-id-type="pmid">14850440</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Du Vigneaud</surname><given-names>V</given-names></name><name><surname>Gash</surname><given-names>DT</given-names></name><name><surname>Katsoyannis</surname><given-names>PG</given-names></name></person-group><article-title>A synthetic preparation possessing biological properties associated with argininevasopressin</article-title><source>J Am Chem Soc</source><year>1954</year><volume>76</volume><fpage>4751</fpage><lpage>4752</lpage></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arnauld</surname><given-names>E</given-names></name><name><surname>Czernichow</surname><given-names>P</given-names></name><name><surname>Fumoux</surname><given-names>F</given-names></name><name><surname>Vincent</surname><given-names>JD</given-names></name></person-group><article-title>The effects of hypotension and hypovolaemia on the liberation of vasopressin during haemorrhage in the unanaesthetized monkey (<italic>Macaca mulatta</italic>)</article-title><source>Pflugers Arch Eur J Physiol</source><year>1977</year><volume>371</volume><fpage>193</fpage><lpage>200</lpage><pub-id pub-id-type="pmid">414200</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cowley</surname><given-names>AW</given-names><suffix>Jr</suffix></name><name><surname>Switzer</surname><given-names>SJ</given-names></name><name><surname>Guinn</surname><given-names>MM</given-names></name></person-group><article-title>Evidence and quantification of the vasopressin arterial pressure control system in the dog</article-title><source>Circ Res</source><year>1980</year><volume>46</volume><fpage>58</fpage><lpage>67</lpage><pub-id pub-id-type="pmid">7349918</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>MF</given-names></name><name><surname>Brackett</surname><given-names>DJ</given-names></name><name><surname>Hinshaw</surname><given-names>LB</given-names></name><name><surname>Tompkins</surname><given-names>P</given-names></name><name><surname>Archer</surname><given-names>LT</given-names></name><name><surname>Benjamin</surname><given-names>BA</given-names></name></person-group><article-title>Vasopressin release during sepsis and septic shock in baboons and dogs</article-title><source>Surg Gynecol Obstet</source><year>1981</year><volume>153</volume><fpage>869</fpage><lpage>872</lpage><pub-id pub-id-type="pmid">7029759</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>MF</given-names></name><name><surname>Brackett</surname><given-names>DJ</given-names></name></person-group><article-title>Release of vasoactive hormones and circulatory changes in shock</article-title><source>Circ Shock</source><year>1983</year><volume>11</volume><fpage>225</fpage><lpage>234</lpage><pub-id pub-id-type="pmid">6360411</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>BC</given-names></name><name><surname>Flora-Ginter</surname><given-names>G</given-names></name><name><surname>Leadley</surname><given-names>RJ</given-names><suffix>Jr</suffix></name><name><surname>Goetz</surname><given-names>KL</given-names></name></person-group><article-title>Ventricular receptors stimulate vasopressin release during hemorrhage</article-title><source>Am J Physiol</source><year>1988</year><volume>254</volume><fpage>R204</fpage><lpage>R211</lpage><pub-id pub-id-type="pmid">3278626</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schwartz</surname><given-names>J</given-names></name><name><surname>Reid</surname><given-names>IA</given-names></name></person-group><article-title>Effect of vasopressin blockade on blood pressure regulation during hemorrhage in conscious dogs</article-title><source>Endocrinology</source><year>1981</year><volume>109</volume><fpage>1778</fpage><lpage>1780</lpage><pub-id pub-id-type="pmid">7028466</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Abboud</surname><given-names>FM</given-names></name><name><surname>Floras</surname><given-names>JS</given-names></name><name><surname>Aylward</surname><given-names>PE</given-names></name><name><surname>Guo</surname><given-names>GB</given-names></name><name><surname>Gupta</surname><given-names>BN</given-names></name><name><surname>Schmid</surname><given-names>PG</given-names></name></person-group><article-title>Role of vasopressin in cardiovascular and blood pressure regulation</article-title><source>Blood Vessels</source><year>1990</year><volume>27</volume><fpage>106</fpage><lpage>115</lpage><pub-id pub-id-type="pmid">2242439</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Errington</surname><given-names>ML</given-names></name><name><surname>Rocha e Silva</surname><given-names>M</given-names><suffix>Jr</suffix></name></person-group><article-title>The secretion and clearance of vasopressin during the development of irreversible haemorrhagic shock</article-title><source>J Physiol (Lond)</source><year>1971</year><volume>217</volume><fpage>43P</fpage><lpage>45P</lpage><pub-id pub-id-type="pmid">5571938</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Landry</surname><given-names>DW</given-names></name><name><surname>Levin</surname><given-names>HR</given-names></name><name><surname>Gallant</surname><given-names>EM</given-names></name><name><surname>Seo</surname><given-names>S</given-names></name><name><surname>D'Alessandro</surname><given-names>D</given-names></name><name><surname>Oz</surname><given-names>MC</given-names></name><name><surname>Oliver</surname><given-names>JA</given-names></name></person-group><article-title>Vasopressin pressor hypersensitivity in vasodilatory septic shock</article-title><source>Crit Care Med</source><year>1997</year><volume>25</volume><fpage>1279</fpage><lpage>1282</lpage><pub-id pub-id-type="pmid">9267938</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Landry</surname><given-names>DW</given-names></name><name><surname>Levin</surname><given-names>HR</given-names></name><name><surname>Gallant</surname><given-names>EM</given-names></name><name><surname>Ashton</surname><given-names>RC</given-names><suffix>Jr</suffix></name><name><surname>Seo</surname><given-names>S</given-names></name><name><surname>D'A-lessandro</surname><given-names>D</given-names></name><name><surname>Oz</surname><given-names>MC</given-names></name><name><surname>Oliver</surname><given-names>JA</given-names></name></person-group><article-title>Vasopressin deficiency contributes to the vasodilation of septic shock</article-title><source>Circulation</source><year>1997</year><volume>95</volume><fpage>1122</fpage><lpage>1125</lpage><pub-id pub-id-type="pmid">9054839</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Morales</surname><given-names>D</given-names></name><name><surname>Madigan</surname><given-names>J</given-names></name><name><surname>Cullinane</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Heath</surname><given-names>M</given-names></name><name><surname>Oz</surname><given-names>M</given-names></name><name><surname>Oliver</surname><given-names>JA</given-names></name><name><surname>Landry</surname><given-names>DW</given-names></name></person-group><article-title>Reversal by vasopressin of intractable hypotension in the late phase of hemorrhagic shock</article-title><source>Circulation</source><year>1999</year><volume>100</volume><fpage>226</fpage><lpage>229</lpage><pub-id pub-id-type="pmid">10411844</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Landry</surname><given-names>DW</given-names></name><name><surname>Oliver</surname><given-names>JA</given-names></name></person-group><article-title>The pathogenesis of vasodilatory shock</article-title><source>N Engl J Med</source><year>2001</year><volume>345</volume><fpage>588</fpage><lpage>595</lpage><pub-id pub-id-type="pmid">11529214</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sharshar</surname><given-names>T</given-names></name><name><surname>Carlier</surname><given-names>R</given-names></name><name><surname>Blanchard</surname><given-names>A</given-names></name><name><surname>Feydy</surname><given-names>A</given-names></name><name><surname>Gray</surname><given-names>F</given-names></name><name><surname>Paillard</surname><given-names>M</given-names></name><name><surname>Raphael</surname><given-names>JC</given-names></name><name><surname>Gajdos</surname><given-names>P</given-names></name><name><surname>Annane</surname><given-names>D</given-names></name></person-group><article-title>Depletion of neurohypophyseal content of vasopressin in septic shock</article-title><source>Crit Care Med</source><year>2002</year><volume>30</volume><fpage>497</fpage><lpage>500</lpage><pub-id pub-id-type="pmid">11990905</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bichet</surname><given-names>DG</given-names></name><name><surname>Razi</surname><given-names>M</given-names></name><name><surname>Lonergan</surname><given-names>M</given-names></name><name><surname>Arthus</surname><given-names>MF</given-names></name><name><surname>Papukna</surname><given-names>V</given-names></name><name><surname>Kortas</surname><given-names>C</given-names></name><name><surname>Barjon</surname><given-names>JN</given-names></name></person-group><article-title>Hemodynamic and coagulation responses to 1-desamino[8-D-arginine] vasopressin in patients with congenital nephrogenic diabetes insipidus</article-title><source>N Engl J Med</source><year>1988</year><volume>318</volume><fpage>881</fpage><lpage>887</lpage><pub-id pub-id-type="pmid">2965301</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Walker</surname><given-names>BR</given-names></name><name><surname>Haynes</surname><given-names>J</given-names><suffix>Jr</suffix></name><name><surname>Wang</surname><given-names>HL</given-names></name><name><surname>Voelkel</surname><given-names>NF</given-names></name></person-group><article-title>Vasopressin-induced pulmonary vasodilation in rats</article-title><source>Am J Physiol</source><year>1989</year><volume>257</volume><fpage>H415</fpage><lpage>H422</lpage><pub-id pub-id-type="pmid">2764128</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Evora</surname><given-names>PR</given-names></name><name><surname>Pearson</surname><given-names>PJ</given-names></name><name><surname>Schaff</surname><given-names>HV</given-names></name></person-group><article-title>Arginine vasopressin induces endothelium-dependent vasodilatation of the pulmonary artery. V1-receptor-mediated production of nitric oxide</article-title><source>Chest</source><year>1993</year><volume>103</volume><fpage>1241</fpage><lpage>1245</lpage><pub-id pub-id-type="pmid">8131474</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>Y</given-names></name><name><surname>Satoh</surname><given-names>S</given-names></name><name><surname>Oyama</surname><given-names>H</given-names></name><name><surname>Takayasu</surname><given-names>M</given-names></name><name><surname>Shibuya</surname><given-names>M</given-names></name></person-group><article-title>Regional differences in the vasodilator response to vasopressin in canine cerebral arteries in vivo</article-title><source>Stroke</source><year>1993</year><volume>24</volume><fpage>1049</fpage><lpage>1053</lpage><pub-id pub-id-type="pmid">7686696</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rudichenko</surname><given-names>VM</given-names></name><name><surname>Beierwaltes</surname><given-names>WH</given-names></name></person-group><article-title>Arginine vasopressin-induced renal vasodilation mediated by nitric oxide</article-title><source>J Vasc Res</source><year>1995</year><volume>32</volume><fpage>100</fpage><lpage>105</lpage><pub-id pub-id-type="pmid">7734655</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tamaki</surname><given-names>T</given-names></name><name><surname>Kiyomoto</surname><given-names>K</given-names></name><name><surname>He</surname><given-names>H</given-names></name><name><surname>Tomohiro</surname><given-names>A</given-names></name><name><surname>Nishiyama</surname><given-names>A</given-names></name><name><surname>Aki</surname><given-names>Y</given-names></name><name><surname>Kimura</surname><given-names>S</given-names></name><name><surname>Abe</surname><given-names>Y</given-names></name></person-group><article-title>Vasodilation induced by vasopressin V2 receptor stimulation in afferent arterioles</article-title><source>Kidney Int</source><year>1996</year><volume>49</volume><fpage>722</fpage><lpage>729</lpage><pub-id pub-id-type="pmid">8648913</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Okamura</surname><given-names>T</given-names></name><name><surname>Toda</surname><given-names>M</given-names></name><name><surname>Ayajiki</surname><given-names>K</given-names></name><name><surname>Toda</surname><given-names>N</given-names></name></person-group><article-title>Receptor subtypes involved in relaxation and contraction by arginine vasopressin in canine isolated short posterior ciliary arteries</article-title><source>J Vasc Res</source><year>1997</year><volume>34</volume><fpage>464</fpage><lpage>472</lpage><pub-id pub-id-type="pmid">9425999</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Okamura</surname><given-names>T</given-names></name><name><surname>Ayajiki</surname><given-names>K</given-names></name><name><surname>Fujioka</surname><given-names>H</given-names></name><name><surname>Toda</surname><given-names>N</given-names></name></person-group><article-title>Mechanisms underlying arginine vasopressin-induced relaxation in monkey isolated coronary arteries</article-title><source>J Hypertens</source><year>1999</year><volume>17</volume><fpage>673</fpage><lpage>678</lpage><pub-id pub-id-type="pmid">10403611</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barberis</surname><given-names>C</given-names></name><name><surname>Mouillac</surname><given-names>B</given-names></name><name><surname>Durroux</surname><given-names>T</given-names></name></person-group><article-title>Structural bases of vasopressin/oxytocin receptor function</article-title><source>J Endocrinol</source><year>1998</year><volume>156</volume><fpage>223</fpage><lpage>229</lpage><pub-id pub-id-type="pmid">9518866</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Swaab</surname><given-names>DF</given-names></name><name><surname>Nijveldt</surname><given-names>F</given-names></name><name><surname>Pool</surname><given-names>CW</given-names></name></person-group><article-title>Distribution of oxytocin and vasopressin in the rat supraoptic and paraventricular nucleus</article-title><source>J Endocrinol</source><year>1975</year><volume>67</volume><fpage>461</fpage><lpage>462</lpage><pub-id pub-id-type="pmid">1206330</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Riddell</surname><given-names>DC</given-names></name><name><surname>Mallonee</surname><given-names>R</given-names></name><name><surname>Phillips</surname><given-names>JA</given-names></name><name><surname>Parks</surname><given-names>JS</given-names></name><name><surname>Sexton</surname><given-names>LA</given-names></name><name><surname>Hamerton</surname><given-names>JL</given-names></name></person-group><article-title>Chromosomal assignment of human sequences encoding arginine vasopressin-neurophysin II and growth hormone releasing factor</article-title><source>Somat Cell Mol Genet</source><year>1985</year><volume>11</volume><fpage>189</fpage><lpage>195</lpage><pub-id pub-id-type="pmid">2984790</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Summar</surname><given-names>ML</given-names></name><name><surname>Phillips</surname><given-names>JA</given-names><suffix>III</suffix></name><name><surname>Battey</surname><given-names>J</given-names></name><name><surname>Castiglione</surname><given-names>CM</given-names></name><name><surname>Kidd</surname><given-names>KK</given-names></name><name><surname>Maness</surname><given-names>KJ</given-names></name><name><surname>Weiffenbach</surname><given-names>B</given-names></name><name><surname>Gravius</surname><given-names>TC</given-names></name></person-group><article-title>Linkage relationships of human arginine vasopressin-neurophysin-II and oxytocin-neurophysin-I to prodynorphin and other loci on chromosome 20</article-title><source>Mol Endocrinol</source><year>1990</year><volume>4</volume><fpage>947</fpage><lpage>950</lpage><pub-id pub-id-type="pmid">1978246</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ruppert</surname><given-names>S</given-names></name><name><surname>Scherer</surname><given-names>G</given-names></name><name><surname>Schutz</surname><given-names>G</given-names></name></person-group><article-title>Recent gene conversion involving bovine vasopressin and oxytocin precursor genes suggested by nucleotide sequence</article-title><source>Nature</source><year>1984</year><volume>308</volume><fpage>554</fpage><lpage>557</lpage><pub-id pub-id-type="pmid">6709064</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Burbach</surname><given-names>J</given-names></name></person-group><article-title>Regulation of gene promoters of hypothalamic peptides</article-title><source>Front Neuroendocrinol</source><year>2002</year><volume>23</volume><fpage>342</fpage><lpage>369</lpage><pub-id pub-id-type="pmid">12381330</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thibonnier</surname><given-names>M</given-names></name><name><surname>Conarty</surname><given-names>DM</given-names></name><name><surname>Preston</surname><given-names>JA</given-names></name><name><surname>Wilkins</surname><given-names>PL</given-names></name><name><surname>Berti-Mattera</surname><given-names>LN</given-names></name><name><surname>Mattera</surname><given-names>R</given-names></name></person-group><article-title>Molecular pharmacology of human vasopressin receptors</article-title><source>Adv Exp Med Biol</source><year>1998</year><volume>449</volume><fpage>251</fpage><lpage>276</lpage><pub-id pub-id-type="pmid">10026814</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zenteno-Savin</surname><given-names>T</given-names></name><name><surname>Sada-Ovalle</surname><given-names>I</given-names></name><name><surname>Ceballos</surname><given-names>G</given-names></name><name><surname>Rubio</surname><given-names>R</given-names></name></person-group><article-title>Effects of arginine vasopressin in the heart are mediated by specific intravascular endothelial receptors</article-title><source>Eur J Pharmacol</source><year>2000</year><volume>410</volume><fpage>15</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">11134652</pub-id></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Neves</surname><given-names>SR</given-names></name><name><surname>Ram</surname><given-names>PT</given-names></name><name><surname>Iyengar</surname><given-names>R</given-names></name></person-group><article-title>G protein pathways</article-title><source>Science</source><year>2002</year><volume>296</volume><fpage>1636</fpage><lpage>1639</lpage><pub-id pub-id-type="pmid">12040175</pub-id></citation></ref><ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Berrada</surname><given-names>K</given-names></name><name><surname>Plesnicher</surname><given-names>CL</given-names></name><name><surname>Luo</surname><given-names>X</given-names></name><name><surname>Thibonnier</surname><given-names>M</given-names></name></person-group><article-title>Dynamic interaction of human vasopressin/oxytocin receptor subtypes with g protein-coupled receptor kinases and protein kinase c after agonist stimulation</article-title><source>J Biol Chem</source><year>2000</year><volume>275</volume><fpage>27229</fpage><lpage>27237</lpage><pub-id pub-id-type="pmid">10858434</pub-id></citation></ref><ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ross</surname><given-names>EM</given-names></name><name><surname>Gilman</surname><given-names>AG</given-names></name></person-group><article-title>Biochemical properties of hormone-sensitive adenylate cyclase</article-title><source>Annu Rev Biochem</source><year>1980</year><volume>49</volume><fpage>533</fpage><lpage>564</lpage><pub-id pub-id-type="pmid">6105841</pub-id></citation></ref><ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Birnbaumer</surname><given-names>M</given-names></name></person-group><article-title>Mutations and diseases of G protein coupled receptors</article-title><source>J Recept Signal Transduct Res</source><year>1995</year><volume>15</volume><fpage>131</fpage><lpage>160</lpage><pub-id pub-id-type="pmid">8903937</pub-id></citation></ref><ref id="B41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Gilbert</surname><given-names>S</given-names></name><name><surname>Birnbaumer</surname><given-names>M</given-names></name><name><surname>Birnbaumer</surname><given-names>L</given-names></name></person-group><article-title>Dual signaling potential is common among Gs-coupled receptors and dependent on receptor density</article-title><source>Mol Pharmacol</source><year>1994</year><volume>46</volume><fpage>460</fpage><lpage>469</lpage><pub-id pub-id-type="pmid">7935326</pub-id></citation></ref><ref id="B42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>U</given-names></name><name><surname>Muller</surname><given-names>C</given-names></name><name><surname>Chu</surname><given-names>P</given-names></name><name><surname>Birnbaumer</surname><given-names>M</given-names></name><name><surname>von Zastrow</surname><given-names>M</given-names></name></person-group><article-title>Heterologous inhibition of G protein-coupled receptor endocytosis mediated by receptor-specific trafficking of beta-arrestins</article-title><source>J Biol Chem</source><year>2001</year><volume>276</volume><fpage>17442</fpage><lpage>17447</lpage><pub-id pub-id-type="pmid">11278476</pub-id></citation></ref><ref id="B43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>CS</given-names></name><name><surname>Kehrl</surname><given-names>JH</given-names></name></person-group><article-title>PYK2 links G(q)alpha and G(13)alpha signaling to NF-kappa B activation</article-title><source>J Biol Chem</source><year>2001</year><volume>276</volume><fpage>31845</fpage><lpage>31850</lpage><pub-id pub-id-type="pmid">11435419</pub-id></citation></ref><ref id="B44"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thibonnier</surname><given-names>M</given-names></name><name><surname>Graves</surname><given-names>MK</given-names></name><name><surname>Wagner</surname><given-names>MS</given-names></name><name><surname>Auzan</surname><given-names>C</given-names></name><name><surname>Clauser</surname><given-names>E</given-names></name><name><surname>Willard</surname><given-names>HF</given-names></name></person-group><article-title>Structure, sequence, expression, and chromosomal localization of the human V1a vasopressin receptor gene</article-title><source>Genomics</source><year>1996</year><volume>31</volume><fpage>327</fpage><lpage>334</lpage><pub-id pub-id-type="pmid">8838314</pub-id></citation></ref><ref id="B45"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Briley</surname><given-names>EM</given-names></name><name><surname>Lolait</surname><given-names>SJ</given-names></name><name><surname>Axelrod</surname><given-names>J</given-names></name><name><surname>Felder</surname><given-names>CC</given-names></name></person-group><article-title>The cloned vasopressin V1a receptor stimulates phospholipase A2, phospholipase C, and phospholipase D through activation of receptor-operated calcium channels</article-title><source>Neuropeptides</source><year>1994</year><volume>27</volume><fpage>63</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">7969820</pub-id></citation></ref><ref id="B46"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Phillips</surname><given-names>PA</given-names></name><name><surname>Abrahams</surname><given-names>JM</given-names></name><name><surname>Kelly</surname><given-names>JM</given-names></name><name><surname>Mooser</surname><given-names>V</given-names></name><name><surname>Trinder</surname><given-names>D</given-names></name><name><surname>Johnston</surname><given-names>CI</given-names></name></person-group><article-title>Localization of vasopressin binding sites in rat tissues using specific V1 and V2 selective ligands</article-title><source>Endocrinology</source><year>1990</year><volume>126</volume><fpage>1478</fpage><lpage>1484</lpage><pub-id pub-id-type="pmid">2307115</pub-id></citation></ref><ref id="B47"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Filep</surname><given-names>J</given-names></name><name><surname>Rosenkranz</surname><given-names>B</given-names></name></person-group><article-title>Mechanism of vasopressin-induced platelet aggregation</article-title><source>Thromb Res</source><year>1987</year><volume>45</volume><fpage>7</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">3105115</pub-id></citation></ref><ref id="B48"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vittet</surname><given-names>D</given-names></name><name><surname>Launay</surname><given-names>JM</given-names></name><name><surname>Chevillard</surname><given-names>C</given-names></name></person-group><article-title>Homologous regulation of human platelet vasopressin receptors does not occur in vivo</article-title><source>Am J Physiol</source><year>1989</year><volume>257</volume><fpage>R1400</fpage><lpage>R1405</lpage><pub-id pub-id-type="pmid">2532481</pub-id></citation></ref><ref id="B49"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lachant</surname><given-names>NA</given-names></name><name><surname>Smith</surname><given-names>MR</given-names></name><name><surname>Xie</surname><given-names>ZJ</given-names></name><name><surname>Romani</surname><given-names>WR</given-names></name></person-group><article-title>Heterogeneity of the aggregation response of human platelets to arginine vasopressin</article-title><source>Am J Hematol</source><year>1995</year><volume>49</volume><fpage>56</fpage><lpage>66</lpage><pub-id pub-id-type="pmid">7741139</pub-id></citation></ref><ref id="B50"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bankir</surname><given-names>L</given-names></name></person-group><article-title>Antidiuretic action of vasopressin: quantitative aspects and interaction between V1a and V2 receptor-mediated effects</article-title><source>Cardiovasc Res</source><year>2001</year><volume>51</volume><fpage>372</fpage><lpage>390</lpage><pub-id pub-id-type="pmid">11476728</pub-id></citation></ref><ref id="B51"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cottet-Maire</surname><given-names>F</given-names></name><name><surname>Avdonin</surname><given-names>PV</given-names></name><name><surname>Roulet</surname><given-names>E</given-names></name><name><surname>Buetler</surname><given-names>TM</given-names></name><name><surname>Mermod</surname><given-names>N</given-names></name><name><surname>Ruegg</surname><given-names>UT</given-names></name></person-group><article-title>Upregulation of vasopressin V1A receptor mRNA and protein in vascular smooth muscle cells following cyclosporin A treatment</article-title><source>Br J Pharmacol</source><year>2001</year><volume>132</volume><fpage>909</fpage><lpage>917</lpage><pub-id pub-id-type="pmid">11181432</pub-id></citation></ref><ref id="B52"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lo Russo</surname><given-names>A</given-names></name><name><surname>Passaquin</surname><given-names>AC</given-names></name><name><surname>Ruegg</surname><given-names>UT</given-names></name></person-group><article-title>Mechanism of enhanced vasoconstrictor hormone action in vascular smooth muscle cells by cyclosporin A</article-title><source>Br J Pharmacol</source><year>1997</year><volume>121</volume><fpage>248</fpage><lpage>252</lpage><pub-id pub-id-type="pmid">9154334</pub-id></citation></ref><ref id="B53"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Edwards</surname><given-names>RM</given-names></name><name><surname>Trizna</surname><given-names>W</given-names></name><name><surname>Kinter</surname><given-names>LB</given-names></name></person-group><article-title>Renal microvascular effects of vasopressin and vasopressin antagonists</article-title><source>Am J Physiol</source><year>1989</year><volume>256</volume><fpage>F274</fpage><lpage>F278</lpage><pub-id pub-id-type="pmid">2916660</pub-id></citation></ref><ref id="B54"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Holmes</surname><given-names>CL</given-names></name><name><surname>Walley</surname><given-names>KR</given-names></name><name><surname>Chittock</surname><given-names>DR</given-names></name><name><surname>Lehman</surname><given-names>T</given-names></name><name><surname>Russell</surname><given-names>JA</given-names></name></person-group><article-title>The effects of vasopressin on hemodynamics and renal function in severe septic shock: a case series</article-title><source>Intensive Care Med</source><year>2001</year><volume>27</volume><fpage>1416</fpage><lpage>1421</lpage><pub-id pub-id-type="pmid">11511958</pub-id></citation></ref><ref id="B55"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>B</given-names></name><name><surname>Chittock</surname><given-names>D</given-names></name><name><surname>Walley</surname><given-names>K</given-names></name></person-group><article-title>Vasopressin infusion in SIRS and septic shock: a randomized controlled trial</article-title><source>Am J Respir Crit Care Med</source><year>1999</year><volume>159</volume><fpage>A608</fpage></citation></ref><ref id="B56"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Innamorati</surname><given-names>G</given-names></name><name><surname>Sadeghi</surname><given-names>H</given-names></name><name><surname>Birnbaumer</surname><given-names>M</given-names></name></person-group><article-title>A fully active nonglycosylated V2 vasopressin receptor</article-title><source>Mol Pharmacol</source><year>1996</year><volume>50</volume><fpage>467</fpage><lpage>473</lpage><pub-id pub-id-type="pmid">8794883</pub-id></citation></ref><ref id="B57"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Erlenbach</surname><given-names>I</given-names></name><name><surname>Wess</surname><given-names>J</given-names></name></person-group><article-title>Molecular basis of V2 vasopressin receptor/Gs coupling selectivity</article-title><source>J Biol Chem</source><year>1998</year><volume>273</volume><fpage>26549</fpage><lpage>26558</lpage><pub-id pub-id-type="pmid">9756892</pub-id></citation></ref><ref id="B58"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Wess</surname><given-names>J</given-names></name></person-group><article-title>Different single receptor domains determine the distinct G protein coupling profiles of members of the vasopressin receptor family</article-title><source>J Biol Chem</source><year>1996</year><volume>271</volume><fpage>8772</fpage><lpage>8778</lpage><pub-id pub-id-type="pmid">8621513</pub-id></citation></ref><ref id="B59"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Birnbaumer</surname><given-names>M</given-names></name></person-group><article-title>Vasopressin receptors</article-title><source>Trends Endocrinol Metab</source><year>2000</year><volume>11</volume><fpage>406</fpage><lpage>410</lpage><pub-id pub-id-type="pmid">11091117</pub-id></citation></ref><ref id="B60"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Orloff</surname><given-names>J</given-names></name><name><surname>Handler</surname><given-names>J</given-names></name></person-group><article-title>The role of adenosine 3',5'-phosphate in the action of antidiuretic hormone</article-title><source>Am J Med</source><year>1967</year><volume>42</volume><fpage>757</fpage><lpage>768</lpage><pub-id pub-id-type="pmid">5337377</pub-id></citation></ref><ref id="B61"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dousa</surname><given-names>TP</given-names></name><name><surname>Walter</surname><given-names>R</given-names></name><name><surname>Schwartz</surname><given-names>IL</given-names></name><name><surname>Sands</surname><given-names>H</given-names></name><name><surname>Hechter</surname><given-names>O</given-names></name></person-group><article-title>Role of cyclic AMP in the action of neurohypophyseal hormones on kidney</article-title><source>Adv Cyclic Nucleotide Res</source><year>1972</year><volume>1</volume><fpage>121</fpage><lpage>135</lpage><pub-id pub-id-type="pmid">4353162</pub-id></citation></ref><ref id="B62"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Harris</surname><given-names>HW</given-names><suffix>Jr</suffix></name><name><surname>Zeidel</surname><given-names>ML</given-names></name><name><surname>Jo</surname><given-names>I</given-names></name><name><surname>Hammond</surname><given-names>TG</given-names></name></person-group><article-title>Characterization of purified endosomes containing the antidiuretic hormone-sensitive water channel from rat renal papilla</article-title><source>J Biol Chem</source><year>1994</year><volume>269</volume><fpage>11993</fpage><lpage>12000</lpage><pub-id pub-id-type="pmid">8163502</pub-id></citation></ref><ref id="B63"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Knepper</surname><given-names>MA</given-names></name><name><surname>Inoue</surname><given-names>T</given-names></name></person-group><article-title>Regulation of aquaporin-2 water channel trafficking by vasopressin</article-title><source>Curr Opin Cell Biol</source><year>1997</year><volume>9</volume><fpage>560</fpage><lpage>564</lpage><pub-id pub-id-type="pmid">9261056</pub-id></citation></ref><ref id="B64"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kambouris</surname><given-names>M</given-names></name><name><surname>Dlouhy</surname><given-names>SR</given-names></name><name><surname>Trofatter</surname><given-names>JA</given-names></name><name><surname>Conneally</surname><given-names>PM</given-names></name><name><surname>Hodes</surname><given-names>ME</given-names></name></person-group><article-title>Localization of the gene for X-linked nephrogenic diabetes insipidus to Xq28</article-title><source>Am J Med Genet</source><year>1988</year><volume>29</volume><fpage>239</fpage><lpage>246</lpage><pub-id pub-id-type="pmid">2894172</pub-id></citation></ref><ref id="B65"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rosenthal</surname><given-names>W</given-names></name><name><surname>Antaramian</surname><given-names>A</given-names></name><name><surname>Gilbert</surname><given-names>S</given-names></name><name><surname>Birnbaumer</surname><given-names>M</given-names></name></person-group><article-title>Nephrogenic diabetes insipidus. A V2 vasopressin receptor unable to stimulate adenylyl cyclase</article-title><source>J Biol Chem</source><year>1993</year><volume>268</volume><fpage>13030</fpage><lpage>13033</lpage><pub-id pub-id-type="pmid">8514744</pub-id></citation></ref><ref id="B66"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rousseau-Merck</surname><given-names>MF</given-names></name><name><surname>Rene</surname><given-names>P</given-names></name><name><surname>Derre</surname><given-names>J</given-names></name><name><surname>Bienvenu</surname><given-names>T</given-names></name><name><surname>Berger</surname><given-names>R</given-names></name><name><surname>de Keyzer</surname><given-names>Y</given-names></name></person-group><article-title>Chromosomal localization of the human V3 pituitary vasopressin receptor gene (AVPR3) to 1q32</article-title><source>Genomics</source><year>1995</year><volume>30</volume><fpage>405</fpage><lpage>406</lpage><pub-id pub-id-type="pmid">8586456</pub-id></citation></ref><ref id="B67"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sugimoto</surname><given-names>T</given-names></name><name><surname>Saito</surname><given-names>M</given-names></name><name><surname>Mochizuki</surname><given-names>S</given-names></name><name><surname>Watanabe</surname><given-names>Y</given-names></name><name><surname>Hashimoto</surname><given-names>S</given-names></name><name><surname>Kawashima</surname><given-names>H</given-names></name></person-group><article-title>Molecular cloning and functional expression of a cDNA encoding the human V1b vasopressin receptor</article-title><source>J Biol Chem</source><year>1994</year><volume>269</volume><fpage>27088</fpage><lpage>27092</lpage><pub-id pub-id-type="pmid">7929452</pub-id></citation></ref><ref id="B68"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thibonnier</surname><given-names>M</given-names></name><name><surname>Preston</surname><given-names>JA</given-names></name><name><surname>Dulin</surname><given-names>N</given-names></name><name><surname>Wilkins</surname><given-names>PL</given-names></name><name><surname>Berti-Mattera</surname><given-names>LN</given-names></name><name><surname>Mattera</surname><given-names>R</given-names></name></person-group><article-title>The human V3 pituitary vasopressin receptor: ligand binding profile and density-dependent signaling pathways</article-title><source>Endocrinology</source><year>1997</year><volume>138</volume><fpage>4109</fpage><lpage>4122</lpage><pub-id pub-id-type="pmid">9322919</pub-id></citation></ref><ref id="B69"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thibonnier</surname><given-names>M</given-names></name><name><surname>Berti-Mattera</surname><given-names>LN</given-names></name><name><surname>Dulin</surname><given-names>N</given-names></name><name><surname>Conarty</surname><given-names>DM</given-names></name><name><surname>Mattera</surname><given-names>R</given-names></name></person-group><article-title>Signal transduction pathways of the human V1-vascular, V2-renal, V3-pituitary vasopressin and oxytocin receptors</article-title><source>Prog Brain Res</source><year>1998</year><volume>119</volume><fpage>147</fpage><lpage>161</lpage><pub-id pub-id-type="pmid">10074787</pub-id></citation></ref><ref id="B70"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>JP</given-names></name><name><surname>Engler</surname><given-names>D</given-names></name><name><surname>Funder</surname><given-names>JW</given-names></name><name><surname>Robinson</surname><given-names>PJ</given-names></name></person-group><article-title>Arginine vasopressin (AVP) causes the reversible phosphorylation of the myristoylated alanine-rich C kinase substrate (MARCKS) protein in the ovine anterior pituitary: evidence that MARCKS phosphorylation is associated with adrenocorticotropin (ACTH) secretion</article-title><source>Mol Cell Endocrinol</source><year>1994</year><volume>101</volume><fpage>247</fpage><lpage>256</lpage><pub-id pub-id-type="pmid">9397959</pub-id></citation></ref><ref id="B71"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>B</given-names></name><name><surname>Yang</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>TH</given-names></name><name><surname>al-Azawi</surname><given-names>N</given-names></name><name><surname>Hsu</surname><given-names>WH</given-names></name></person-group><article-title>Effect of AVP and oxytocin on insulin release: involvement of V1b receptors</article-title><source>Am J Physiol</source><year>1995</year><volume>269</volume><fpage>E1095</fpage><lpage>E1100</lpage><pub-id pub-id-type="pmid">8572202</pub-id></citation></ref><ref id="B72"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Peter</surname><given-names>J</given-names></name><name><surname>Burbach</surname><given-names>H</given-names></name><name><surname>Adan</surname><given-names>RA</given-names></name><name><surname>Lolait</surname><given-names>SJ</given-names></name><name><surname>van Leeuwen</surname><given-names>FW</given-names></name><name><surname>Mezey</surname><given-names>E</given-names></name><name><surname>Palkovits</surname><given-names>M</given-names></name><name><surname>Barberis</surname><given-names>C</given-names></name></person-group><article-title>Molecular neurobiology and pharmacology of the vasopressin/oxytocin receptor family</article-title><source>Cell Mol Neurobiol</source><year>1995</year><volume>15</volume><fpage>573</fpage><lpage>595</lpage><pub-id pub-id-type="pmid">8719042</pub-id></citation></ref><ref id="B73"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gimpl</surname><given-names>G</given-names></name><name><surname>Fahrenholz</surname><given-names>F</given-names></name></person-group><article-title>The oxytocin receptor system: structure, function, and regulation</article-title><source>Physiol Rev</source><year>2001</year><volume>81</volume><fpage>629</fpage><lpage>683</lpage><pub-id pub-id-type="pmid">11274341</pub-id></citation></ref><ref id="B74"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sanborn</surname><given-names>BM</given-names></name><name><surname>Dodge</surname><given-names>K</given-names></name><name><surname>Monga</surname><given-names>M</given-names></name><name><surname>Qian</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Yue</surname><given-names>C</given-names></name></person-group><article-title>Molecular mechanisms regulating the effects of oxytocin on myometrial intracellular calcium</article-title><source>Adv Exp Med Biol</source><year>1998</year><volume>449</volume><fpage>277</fpage><lpage>286</lpage><pub-id pub-id-type="pmid">10026815</pub-id></citation></ref><ref id="B75"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thibonnier</surname><given-names>M</given-names></name><name><surname>Conarty</surname><given-names>DM</given-names></name><name><surname>Preston</surname><given-names>JA</given-names></name><name><surname>Plesnicher</surname><given-names>CL</given-names></name><name><surname>Dweik</surname><given-names>RA</given-names></name><name><surname>Erzurum</surname><given-names>SC</given-names></name></person-group><article-title>Human vascular endothelial cells express oxytocin receptors</article-title><source>Endocrinology</source><year>1999</year><volume>140</volume><fpage>1301</fpage><lpage>1309</lpage><pub-id pub-id-type="pmid">10067857</pub-id></citation></ref><ref id="B76"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gutkowska</surname><given-names>J</given-names></name><name><surname>Jankowski</surname><given-names>M</given-names></name><name><surname>Lambert</surname><given-names>C</given-names></name><name><surname>Mukaddam-Daher</surname><given-names>S</given-names></name><name><surname>Zingg</surname><given-names>HH</given-names></name><name><surname>McCann</surname><given-names>SM</given-names></name></person-group><article-title>Oxytocin releases atrial natriuretic peptide by combining with oxytocin receptors in the heart</article-title><source>Proc Natl Acad Sci USA</source><year>1997</year><volume>94</volume><fpage>11704</fpage><lpage>11709</lpage><pub-id pub-id-type="pmid">9326674</pub-id></citation></ref><ref id="B77"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Paquin</surname><given-names>J</given-names></name><name><surname>Danalache</surname><given-names>BA</given-names></name><name><surname>Jankowski</surname><given-names>M</given-names></name><name><surname>McCann</surname><given-names>SM</given-names></name><name><surname>Gutkowska</surname><given-names>J</given-names></name></person-group><article-title>Oxytocin induces differentiation of P19 embryonic stem cells to cardiomyocytes</article-title><source>Proc Natl Acad Sci USA</source><year>2002</year><volume>99</volume><fpage>9550</fpage><lpage>9555</lpage><pub-id pub-id-type="pmid">12093924</pub-id></citation></ref><ref id="B78"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Boarder</surname><given-names>MR</given-names></name><name><surname>Weisman</surname><given-names>GA</given-names></name><name><surname>Turner</surname><given-names>JT</given-names></name><name><surname>Wilkinson</surname><given-names>GF</given-names></name></person-group><article-title>G protein-coupled P2 purinoceptors: from molecular biology to functional responses</article-title><source>Trends Pharmacol Sci</source><year>1995</year><volume>16</volume><fpage>133</fpage><lpage>139</lpage><pub-id pub-id-type="pmid">7610499</pub-id></citation></ref><ref id="B79"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mei</surname><given-names>Q</given-names></name><name><surname>Liang</surname><given-names>BT</given-names></name></person-group><article-title>P2 purinergic receptor activation enhances cardiac contractility in isolated rat and mouse hearts</article-title><source>Am J Physiol Heart Circ Physiol</source><year>2001</year><volume>281</volume><fpage>H334</fpage><lpage>H341</lpage><pub-id pub-id-type="pmid">11406501</pub-id></citation></ref><ref id="B80"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>JS</given-names></name><name><surname>Christie</surname><given-names>A</given-names></name><name><surname>De Young</surname><given-names>MB</given-names></name><name><surname>Levy</surname><given-names>MN</given-names></name><name><surname>Scarpa</surname><given-names>A</given-names></name></person-group><article-title>Synergism between cAMP and ATP in signal transduction in cardiac myocytes</article-title><source>Am J Physiol</source><year>1992</year><volume>262</volume><fpage>C128</fpage><lpage>C135</lpage><pub-id pub-id-type="pmid">1310205</pub-id></citation></ref><ref id="B81"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Diaz Brinton</surname><given-names>R</given-names></name><name><surname>Brownson</surname><given-names>EA</given-names></name></person-group><article-title>Vasopressin-induction of cyclic AMP in cultured hippocampal neurons</article-title><source>Brain Res Dev Brain Res</source><year>1993</year><volume>71</volume><fpage>101</fpage><lpage>105</lpage><pub-id pub-id-type="pmid">8381727</pub-id></citation></ref><ref id="B82"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>de Wied</surname><given-names>D</given-names></name><name><surname>Elands</surname><given-names>J</given-names></name><name><surname>Kovacs</surname><given-names>G</given-names></name></person-group><article-title>Interactive effects of neurohypophyseal neuropeptides with receptor antagonists on passive avoidance behavior: mediation by a cerebral neurohypophyseal hormone receptor?</article-title><source>Proc Natl Acad Sci USA</source><year>1991</year><volume>88</volume><fpage>1494</fpage><lpage>1498</lpage><pub-id pub-id-type="pmid">1847526</pub-id></citation></ref><ref id="B83"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Freedman</surname><given-names>NJ</given-names></name><name><surname>Lefkowitz</surname><given-names>RJ</given-names></name></person-group><article-title>Desensitization of G protein-coupled receptors</article-title><source>Recent Prog Horm Res</source><year>1996</year><volume>51</volume><fpage>319</fpage><lpage>351</lpage><pub-id pub-id-type="pmid">8701085</pub-id></citation></ref><ref id="B84"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chuang</surname><given-names>TT</given-names></name><name><surname>Iacovelli</surname><given-names>L</given-names></name><name><surname>Sallese</surname><given-names>M</given-names></name><name><surname>De Blasi</surname><given-names>A</given-names></name></person-group><article-title>G protein-coupled receptors: heterologous regulation of homologous desensitization and its implications</article-title><source>Trends Pharmacol Sci</source><year>1996</year><volume>17</volume><fpage>416</fpage><lpage>421</lpage><pub-id pub-id-type="pmid">8990958</pub-id></citation></ref><ref id="B85"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Perry</surname><given-names>SJ</given-names></name><name><surname>Baillie</surname><given-names>GS</given-names></name><name><surname>Kohout</surname><given-names>TA</given-names></name><name><surname>McPhee</surname><given-names>I</given-names></name><name><surname>Magiera</surname><given-names>MM</given-names></name><name><surname>Ang</surname><given-names>KL</given-names></name><name><surname>Miller</surname><given-names>WE</given-names></name><name><surname>McLean</surname><given-names>AJ</given-names></name><name><surname>Conti</surname><given-names>M</given-names></name><name><surname>Houslay</surname><given-names>MD</given-names></name><name><surname>Lefkowitz</surname><given-names>RJ</given-names></name></person-group><article-title>Targeting of cyclic AMP degradation to beta 2-adrenergic receptors by beta-arrestins</article-title><source>Science</source><year>2002</year><volume>298</volume><fpage>834</fpage><lpage>836</lpage><pub-id pub-id-type="pmid">12399592</pub-id></citation></ref><ref id="B86"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Turnbaugh</surname><given-names>D</given-names></name><name><surname>Cofie</surname><given-names>D</given-names></name><name><surname>Dogan</surname><given-names>S</given-names></name><name><surname>Koshida</surname><given-names>H</given-names></name><name><surname>Fugate</surname><given-names>R</given-names></name><name><surname>Kem</surname><given-names>DC</given-names></name></person-group><article-title>Protein kinase C modulation of cardiomyocyte angiotensin II and vasopressin receptor desensitization</article-title><source>Hypertension</source><year>1996</year><volume>27</volume><fpage>269</fpage><lpage>275</lpage><pub-id pub-id-type="pmid">8567051</pub-id></citation></ref><ref id="B87"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oakley</surname><given-names>RH</given-names></name><name><surname>Laporte</surname><given-names>SA</given-names></name><name><surname>Holt</surname><given-names>JA</given-names></name><name><surname>Barak</surname><given-names>LS</given-names></name><name><surname>Caron</surname><given-names>MG</given-names></name></person-group><article-title>Association of beta-arrestin with G protein-coupled receptors during clathrin-mediated endocytosis dictates the profile of receptor resensitization</article-title><source>J Biol Chem</source><year>1999</year><volume>274</volume><fpage>32248</fpage><lpage>32257</lpage><pub-id pub-id-type="pmid">10542263</pub-id></citation></ref><ref id="B88"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Innamorati</surname><given-names>G</given-names></name><name><surname>Sadeghi</surname><given-names>H</given-names></name><name><surname>Birnbaumer</surname><given-names>M</given-names></name></person-group><article-title>Phosphorylation and recycling kinetics of G protein-coupled receptors</article-title><source>J Recept Signal Transduct Res</source><year>1999</year><volume>19</volume><fpage>315</fpage><lpage>326</lpage><pub-id pub-id-type="pmid">10071767</pub-id></citation></ref><ref id="B89"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Karmazyn</surname><given-names>M</given-names></name><name><surname>Manku</surname><given-names>MS</given-names></name><name><surname>Horrobin</surname><given-names>DF</given-names></name></person-group><article-title>Changes of vascular reactivity induced by low vasopressin concentrations: interactions with cortisol and lithium and possible involvement of prostaglandins</article-title><source>Endocrinology</source><year>1978</year><volume>102</volume><fpage>1230</fpage><lpage>1236</lpage><pub-id pub-id-type="pmid">744021</pub-id></citation></ref><ref id="B90"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Noguera</surname><given-names>I</given-names></name><name><surname>Medina</surname><given-names>P</given-names></name><name><surname>Segarra</surname><given-names>G</given-names></name><name><surname>Martinez</surname><given-names>MC</given-names></name><name><surname>Aldasoro</surname><given-names>M</given-names></name><name><surname>Vila</surname><given-names>JM</given-names></name><name><surname>Lluch</surname><given-names>S</given-names></name></person-group><article-title>Potentiation by vasopressin of adrenergic vasoconstriction in the rat isolated mesenteric artery</article-title><source>Br J Pharmacol</source><year>1997</year><volume>122</volume><fpage>431</fpage><lpage>438</lpage><pub-id pub-id-type="pmid">9351498</pub-id></citation></ref><ref id="B91"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Laugwitz</surname><given-names>KL</given-names></name><name><surname>Ungerer</surname><given-names>M</given-names></name><name><surname>Schoneberg</surname><given-names>T</given-names></name><name><surname>Weig</surname><given-names>HJ</given-names></name><name><surname>Kronsbein</surname><given-names>K</given-names></name><name><surname>Moretti</surname><given-names>A</given-names></name><name><surname>Hoffmann</surname><given-names>K</given-names></name><name><surname>Seyfarth</surname><given-names>M</given-names></name><name><surname>Schultz</surname><given-names>G</given-names></name><name><surname>Schomig</surname><given-names>A</given-names></name></person-group><article-title>Adenoviral gene transfer of the human V2 vasopressin receptor improves contractile force of rat cardiomyocytes</article-title><source>Circulation</source><year>1999</year><volume>99</volume><fpage>925</fpage><lpage>933</lpage><pub-id pub-id-type="pmid">10027817</pub-id></citation></ref><ref id="B92"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hibert</surname><given-names>M</given-names></name><name><surname>Hoflack</surname><given-names>J</given-names></name><name><surname>Trumpp-Kallmeyer</surname><given-names>S</given-names></name><name><surname>Mouillac</surname><given-names>B</given-names></name><name><surname>Chini</surname><given-names>B</given-names></name><name><surname>Mahe</surname><given-names>E</given-names></name><name><surname>Cotte</surname><given-names>N</given-names></name><name><surname>Jard</surname><given-names>S</given-names></name><name><surname>Manning</surname><given-names>M</given-names></name><name><surname>Barberis</surname><given-names>C</given-names></name></person-group><article-title>Functional architecture of vasopressin/oxytocin receptors</article-title><source>J Recept Signal Transduct Res</source><year>1999</year><volume>19</volume><fpage>589</fpage><lpage>596</lpage><pub-id pub-id-type="pmid">10071787</pub-id></citation></ref><ref id="B93"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bankowski</surname><given-names>K</given-names></name><name><surname>Manning</surname><given-names>M</given-names></name><name><surname>Haldar</surname><given-names>J</given-names></name><name><surname>Sawyer</surname><given-names>WH</given-names></name></person-group><article-title>Design of potent antagonists of the vasopressor response to argininevasopressin</article-title><source>J Med Chem</source><year>1978</year><volume>21</volume><fpage>850</fpage><lpage>853</lpage><pub-id pub-id-type="pmid">722751</pub-id></citation></ref><ref id="B94"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Manning</surname><given-names>MSWH</given-names></name></person-group><article-title>Discovery, development, and some uses of vasopressin and oxytocin antagonists</article-title><source>J Lab Clin Med</source><year>1989</year><volume>114</volume><fpage>617</fpage><lpage>632</lpage><pub-id pub-id-type="pmid">2687422</pub-id></citation></ref><ref id="B95"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Holmes</surname><given-names>CL</given-names></name><name><surname>Patel</surname><given-names>BM</given-names></name><name><surname>Russell</surname><given-names>JA</given-names></name><name><surname>Walley</surname><given-names>KR</given-names></name></person-group><article-title>Physiology of vasopressin relevant to management of septic shock</article-title><source>Chest</source><year>2001</year><volume>120</volume><fpage>989</fpage><lpage>1002</lpage><pub-id pub-id-type="pmid">11555538</pub-id></citation></ref><ref id="B96"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thibonnier</surname><given-names>M</given-names></name><name><surname>Coles</surname><given-names>P</given-names></name><name><surname>Thibonnier</surname><given-names>A</given-names></name><name><surname>Shoham</surname><given-names>M</given-names></name></person-group><article-title>Molecular pharmacology and modeling of vasopressin receptors</article-title><source>Prog Brain Res</source><year>2002</year><volume>139</volume><fpage>179</fpage><lpage>196</lpage><pub-id pub-id-type="pmid">12436935</pub-id></citation></ref></ref-list><sec sec-type="display-objects"><title>Figures and Tables</title><fig position="float" id="F1"><label>Figure 1</label><caption><p>Hypothalamic nuclei involved in vasopressin control. The hypothalamus surrounds the third ventricle ventral to the hypothalamic sulci. The main hypothalamic nuclei subserving vasopressin control are the median preoptic nucleus (MNPO), the paraventricular nuclei (PVN), and the supraoptic nuclei (SON), which project to the posterior pituitary along the supraoptic&#x02013;hypophyseal tract. Afferent nerve impulses from stretch receptors in the left atrium (inhibitory), aortic arch, and carotid sinuses (excitatory) travel via the vagus nerve, and neural pathways project to the PVN and the SON. These nuclei also receive osmotic input from the lamina terminalis, which is excluded from the blood&#x02013;brain barrier and is thus affected by systemic osmolality. Vasopressin is synthesized in the cell bodies of the magnocellular neurons located in the PVN and SON. The magnocellular neurons of the SON are directly depolarized by hypertonic conditions (hence releasing more vasopressin) and hyperpolarized by hypotonic conditions (hence releasing less vasopressin). Finally, vasopressin migrates (in its prohormone state) along the supraoptic&#x02013;hypophyseal tract to the posterior pituitary, where it is released into the circulation. Used by permission from <italic>Chest </italic>[<xref ref-type="bibr" rid="B95">95</xref>].</p></caption><graphic xlink:href="cc2337-1"/></fig><fig position="float" id="F2"><label>Figure 2</label><caption><p>Vasopressin docking and transmembrane topology of the human V<sub>1 </sub>vascular receptor (V<sub>1</sub>R). A model of arginine vasopressin (AVP), as bound to the human V<sub>1</sub>R, is depicted. Vasopressin is shown in ball-and-stick representation and the receptor is shown in ribbons. The intracellular loops of the receptor are labeled il1, il2, and il3, and the extracellular loops are labeled el1, el2, and el3. The transmembrane segments are labeled H1&#x02013;H7. Reprinted from Thibonnier M, Coles P, Thibonnier A, Shoham M: <bold>Molecular pharmacology and modeling of vasopressin receptors. </bold><italic>Prog Brain Res </italic>2002, <bold>139</bold>:179&#x02013;196. &#x000a9; 2002, with permission from Elsevier [<xref ref-type="bibr" rid="B96">96</xref>].</p></caption><graphic xlink:href="cc2337-2"/></fig></sec></back></article> 